Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986207

Next Previous
Drug Profile

BMS 986207

Alternative Names: Anti-TIGIT antibody - Bristol Myers Squibb; BMS-986207; ONO-4686

Latest Information Update: 26 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Compugen; Multiple Myeloma Research Consortium; Ono Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Multiple myeloma; Solid tumours

Most Recent Events

  • 15 May 2024 Compugen completes phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT04570839)
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 25 Jan 2024 Bristol-Myers Squibb completes a phase I/II trial in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA, Australia, Argentina, Canada, Chile, Japan, Romania and Singapore (Parenteral) (NCT02913313)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top